Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoronaVac in Pulmonary Tuberculosis Patients
NCT05148949Phase 4Unknown
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of coronavac in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: Incidence of adverse reaction within 28 days after each dose and GMT of neutralizing antibodies against live SARS-CoV-2 virus. Status: unknown.
02
Drugs
coronavac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05148949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05148949.